Are your prescription drugs affordable? Colorado board wants feedback on these 2
DENVER (KDVR) — A Colorado board continues reviewing the cost of prescription drugs, and public feedback is wanted about the latest two under review.
Cosentyx, which treats psoriasis, and Stelara, for Crohn’s disease, are now under the microscope of the Prescription Drug Affordability Board. The body was created in 2021 to review prescription drugs and evaluate their affordability for Coloradans, and it has the legal authority to cap prices.
Mother loses $16K after unknowingly buying stolen car on Facebook Marketplace
The board recently declared the arthritis medication Enbrel unaffordable and moved to cap its price. But Amgen, its manufacturer, is challenging the move in federal court.
Another two drugs — the HIV treatment Genvoya and the cystic fibrosis drug Trikafta — were not found to be unaffordable, according to the board’s findings.
As part of its review of Cosentyx and Stelara, the affordability board wants feedback from patients, caregivers and people with scientific or medical training. The surveys will be open until April 30.
The survey for patients and caregivers is linked here, and the survey for people with scientific or medical training is linked here.
Prescription drug affordability under the radar in Colorado
Cosentyx and Stelara are among 244 prescription drugs on the affordability board’s priority list, with some 604 eligible for review.
20 prescription drugs on Colorado’s affordability radar
The priority list was put together through a weighted scale based on the number of patients, the change in wholesale acquisition cost, patient out-of-pocket cost, total paid and average paid per person per year.
The list is neither binding nor required by law and is instead “meant to be a tool to present data and spark discussion,” according to the board.
For the latest news, weather, sports, and streaming video, head to FOX31 Denver.
